Forefront Analytics LLC Invests $139,000 in Immatics (NASDAQ:IMTX)

Forefront Analytics LLC bought a new position in shares of Immatics (NASDAQ:IMTX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,987 shares of the company’s stock, valued at approximately $139,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Trexquant Investment LP lifted its holdings in shares of Immatics by 4.2% during the fourth quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock worth $471,000 after purchasing an additional 1,801 shares during the period. AlphaCentric Advisors LLC increased its holdings in Immatics by 14.3% in the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock valued at $232,000 after purchasing an additional 2,500 shares during the period. Nan Fung Group Holdings Ltd acquired a new stake in shares of Immatics in the first quarter valued at about $165,000. The Manufacturers Life Insurance Company increased its stake in shares of Immatics by 13.9% in the second quarter. The Manufacturers Life Insurance Company now owns 150,769 shares of the company’s stock valued at $1,752,000 after buying an additional 18,354 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in shares of Immatics during the fourth quarter worth about $232,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Price Performance

Shares of NASDAQ IMTX opened at $11.73 on Friday. The company has a market capitalization of $993.04 million, a PE ratio of -11.07 and a beta of 0.75. Immatics has a twelve month low of $7.15 and a twelve month high of $13.77. The firm has a fifty day simple moving average of $11.73 and a 200 day simple moving average of $11.55.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.17. The business had revenue of $20.19 million for the quarter, compared to analysts’ expectations of $12.36 million. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. As a group, equities analysts expect that Immatics will post -0.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a report on Thursday, September 5th.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.